research reports and media, page-122

Hmm looking at the following table from a different website there were some AE's..though the commentary here suggests that overall it has a "favorable" safety profile? Wern't there like 4 deaths out of a sample of 2000 and a heap of Serious TEAE's?????

Maybe I'm not reading it right, here is the link:


https://acrabstracts.org/abstract/rheumatoid-arthritis-treatment-with-filgotinib-week-132-safety-data-from-a-phase-2b-open-label-extension-study/


I would like to see PPS's comparative table, I don't think we have had any AE's. Maybe a few upset stomachs and the odd headache and a little bruising around the injection site, cosmetic effects at best?

If Filgtiib has a favorable profile surely ours is 'very favorable' or even 'out of this world favorable' (sorry, I'm being flippant)

Here is the table I'm referring to for Filgotinib.

Conclusion:

Filgotinib continues to demonstrate a favorable safety and tolerability profile in pts with RA over a 2.5-year period, with maintenance of therapeutic response in the long-term.

Table 1: Key Safety Events Per 100 PYE

	Filgotinib (200mg daily) + MTX	Filgotinib (200mg daily) Monotherapy	Total*
	PYE=1443	PYE=599	PYE=2042
Treatment-emergent AEs (TEAEs)	144.1	151.5	146.3
Serious TEAEs	5.1	6.8	5.6
TEAEs for Infections	41.6	36	40
Serious TEAEs for Infections	0.8	1.7	1
Malignancy (excluding NMSC†)	0.6	0.7	0.6
Herpes Zoster	1.5	1.5	1.5
Deep Vein Thrombosis‡	0.07	0	0.05
Pulmonary Embolism‡	0.07	0	0.05
Active Tuberculosis	0	0	0
Deaths	0.1	0.5	0.2

^*Treatment groups with fewer than 10 subjects were omitted for clarity;^†Non-melanoma skin cancer;
^‡Single patient DVT leading to PE.